header
Image from OpenLibrary

The role of hydrogen sulfide in enhancing the effectiveness of mesenchymal stem cell therapy in experimental model of heart failure / Maha Abdelmonem Mohammed Ahmed ; Supervised Amira A. Shaheen , Laila A. Rashed , Nancy N. Shahin

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Maha Abdelmonem Mohammed Ahmed , 2019Description: 93 P. : charts , facimiles ; 25cmOther title:
  • دور كبريتيد الهيدروجين في زيادة فاعلية العلاج بالخلايا الجذعية الوسيطة في نموذج تجريبي لقصورالقلب [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (Ph.D.) - Cairo University -Faculty of Pharmacy - Department of Biochemistry Summary: Stem cell therapy represents a promising therapeutic avenue for cardiac disorders including heart failure. Although stem cell transplantation showed encouraging preliminary results, the outcomes of clinical studies are still unsatisfactory. This study aimed to compare the outcomes of two therapeutic approaches, in vivo co-delivery of sodium hydrogen sulfide (NaHS) concomitantly with bone marrow-derived mesenchymal stem cells (BMSCs) transplantation and in vitro preconditioning of BMSCs with NaHS, for promoting stem cell therapy in rats with isoprenaline-induced heart failure. Heart failure was developed 4 weeks after subcutaneous injection of isoprenaline (170 mg/kg) for 4 consecutive days. The in vivo approach involved co-delivery of intraperitoneally administered NaHS concomitantly with BMSC transplantation for a period of 14 days. The in vitro approach involved preconditioning of BMSC with NaHS for 30 min before transplantation. Compared to treatment with BMSCs alone, in vitro preconditioning of BMSCs with NaHS improved left ventricular function as measured by echocardiography and electrocardiography and enhanced stem cell homing, proliferation and differentiation as manifested by higher cardiac expression of GATA-4 and myocyte enhancer factor 2. Moreover, measurement of cardiac transforming growth factor beta 1level and histopathological investigation revealed mitigated fibrosis and myocardial injury score. The in vivo approach enhanced stem cell homing and differentiation, alleviated fibrosis and augmented vascular endothelial growth factor (VEGF)andendothelial nitric oxide synthase (eNOS) expression compared with BMSC therapy alone
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Date due Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.08.01.Ph.D.2019.Ma.R (Browse shelf(Opens below)) Not for loan 01010110079528000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.08.01.Ph.D.2019.Ma.R (Browse shelf(Opens below)) 79528.CD Not for loan 01020110079528000

Thesis (Ph.D.) - Cairo University -Faculty of Pharmacy - Department of Biochemistry

Stem cell therapy represents a promising therapeutic avenue for cardiac disorders including heart failure. Although stem cell transplantation showed encouraging preliminary results, the outcomes of clinical studies are still unsatisfactory. This study aimed to compare the outcomes of two therapeutic approaches, in vivo co-delivery of sodium hydrogen sulfide (NaHS) concomitantly with bone marrow-derived mesenchymal stem cells (BMSCs) transplantation and in vitro preconditioning of BMSCs with NaHS, for promoting stem cell therapy in rats with isoprenaline-induced heart failure. Heart failure was developed 4 weeks after subcutaneous injection of isoprenaline (170 mg/kg) for 4 consecutive days. The in vivo approach involved co-delivery of intraperitoneally administered NaHS concomitantly with BMSC transplantation for a period of 14 days. The in vitro approach involved preconditioning of BMSC with NaHS for 30 min before transplantation. Compared to treatment with BMSCs alone, in vitro preconditioning of BMSCs with NaHS improved left ventricular function as measured by echocardiography and electrocardiography and enhanced stem cell homing, proliferation and differentiation as manifested by higher cardiac expression of GATA-4 and myocyte enhancer factor 2. Moreover, measurement of cardiac transforming growth factor beta 1level and histopathological investigation revealed mitigated fibrosis and myocardial injury score. The in vivo approach enhanced stem cell homing and differentiation, alleviated fibrosis and augmented vascular endothelial growth factor (VEGF)andendothelial nitric oxide synthase (eNOS) expression compared with BMSC therapy alone

Issued also as CD

There are no comments on this title.

to post a comment.